Valeant Pharmaceuticals International (VRX) : $131.69 million worth of transactions were on upticks in Valeant Pharmaceuticals International (VRX), compared to $124.66 million on downticks. The ratio between the two was 1.06, whereas, the net money flow stood at a healthy $7.03 million on Fridays session.The block trades show a bullish bias with only $8.58 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $13.53million worth of trades. The up-down ratio between the uptick and downtick was 1.58, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $4.95 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -6.78%. The stock was trading at $22.82, with a drop of $1.66 over the previous days close. The stock recorded -0.17% for the week.
Valeant Pharmaceuticals International (VRX) : The most positive equity analysts on Valeant Pharmaceuticals International (VRX) expects the shares to touch $90, whereas, the least positive believes that the stock will trade at $11 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $39.75 with an expected fluctuation of $19.53 from the mean.
Valeant Pharmaceuticals International (NYSE:VRX): On Fridays trading session , Opening price of the stock was $24.2 with an intraday high of $24.3. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $22.72. However, the stock managed to close at $22.82, a loss of 6.78% for the day. On the previous day, the stock had closed at $24.48. The total traded volume of the day was 23,491,879 shares.
In a related news, Ross Thomas W. Sr., Director of Valeant Pharmaceuticals International, Inc., executed a transaction worth $97,600 on June 13, 2016. A total of 4,000 shares were purchased at an average price of $24.4. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.